UBS lowered the firm’s price target on Biohaven (BHVN) to $26 from $27 and keeps a Buy rating on the shares. UBS sees meaningful upside to the stock if troriluzole is approved, and its base case models a 40% probability of success with an estimated PDUFA date in mid-November, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN: